Madrigal Pharmaceuticals, Inc. MDGL
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -26.10%
- 1 year
- +0.66%
- Open
- 431.55
- Prev close
- 431.70
- Mkt cap
- 9.94B
- Vol
- 251.66K
- Avg vol
- 278.50K
- EPS
- -12.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 425.00
- High
- 437.80
- Forward P/E
- 44.71
- Beta
- -1.05
- Short ratio
- 7.90
- Inst. own
- 104.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 500.44
- 200-d avg
- 500.32
- 1y target
- 685.22
5D chart
Signals (119)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 11:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:55 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:35 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 4 days ago |
| RSI: Oversold | Oct 28, 10:15 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| RSI: Oversold | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:25 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:40 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
5 days ago zacks.com
Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know
Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago globenewswire.com
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Rezdiffra ® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and…
6 days ago seekingalpha.com
Baron Health Care Fund: Q3 2026 New Positions And Exits
During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early…
1 week ago seekingalpha.com
Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise
Madrigal Pharmaceuticals is transitioning from hypergrowth to a self-funding franchise, with Rezdiffra now covering enterprise costs ahead of key 2027 data. Q2 net sales grew 71% to $364.3M, with…
1 week ago globenewswire.com
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
CONSHOHOCKEN, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2026 financial results on Tuesday, November…
2 weeks ago globenewswire.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic…
2 weeks ago defenseworld.net
Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)
Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
-
3 weeks ago benzinga.com
Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the…
3 weeks ago globenewswire.com
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct. 06,…
-
1 month ago benzinga.com
Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.
-
1 month ago benzinga.com
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725
Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target of $725.
1 month ago globenewswire.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic…
1 month ago defenseworld.net
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 1,800 Madrigal Pharmaceuticals, Inc. $MDGL
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the second quarter, according to the company in its most recent disclosure…
1 month ago seekingalpha.com
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
1 month ago fool.com
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
Madrigal's only commercial drug, Rezdiffra, continues to grow sales. Institutional investors hold more than 95% of the stock's float.
2 months ago globenewswire.com
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
CONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference…
2 months ago defenseworld.net
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of “Moderate Buy” by Analysts
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eighteen research firms that are currently covering the company,…
2 months ago fool.com
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
MASH cirrhosis could significantly expand Rezdiffra's addressable market. Madrigal's developing pipeline could reduce its dependence on Rezdiffra.
2 months ago defenseworld.net
Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL
Allworth Financial LP bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the second quarter, according to the company in its most recent filing with the SEC. The fund…
2 months ago globenewswire.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic…
2 months ago benzinga.com
This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold
Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.
2 months ago defenseworld.net
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals (NASDAQ: MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH…
2 months ago marketbeat.com
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals NASDAQ: MDGL said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH…
2 months ago gurufocus.com
John Paulson's Top Q2 2026 Move: Exiting Agnico Eagle Mines Ltd at a -5.11% Portfolio Impact
Paulson and Co. reshapes portfolio with a major gold stock exit and a new tech positionJohn Paulson (Trades, Portfolio), President and Portfolio Manager of Paulso
2 months ago benzinga.com
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinions and price targets for these stocks.
-
2 months ago benzinga.com
Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target
Wolfe Research analyst Andy Chen upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Peer Perform to Outperform and announces $605 price target.
-
3 months ago benzinga.com
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962
Barclays analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and lowers the price target from $964 to $962.
-
3 months ago benzinga.com
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses…
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $578 to $587.
3 months ago benzinga.com
4 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
3 months ago benzinga.com
Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685
Wells Fargo analyst Sadia Rahman initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $685.
-
3 months ago benzinga.com
Madrigal Pharmaceuticals Receives Three Resmetirom Patents From U.S. Patent And Trademark Office
New U.S. Rezdiffra patents in F2/F3 to be listed in FDA’s Orange BookU.S. Patent No. 12,667,575, directed to administering a weight-threshold step-down 60mg or 80mg resmetirom dose for patients with…
-
4 months ago benzinga.com
B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542
B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $550 to $542.
-
5 months ago benzinga.com
Madrigal Pharma Announces New Analyses Of Phase 3 Data And Real-World Evidence Demonstrating Rezdiffra Reduced Markers Of Cardiovascular And Liver-Related Risk In Patients With MASH
Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASHRezdiffra improved atherogenic lipid profiles…
-
5 months ago benzinga.com
Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $640 to $709.
-
5 months ago benzinga.com
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $578
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $587 to $578.
-
5 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $649
Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and lowers the price target from $652 to $649.
5 months ago benzinga.com
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target
HC Wainwright & Co. analyst Andrew S. Fein reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and maintains $620 price target.
-
5 months ago benzinga.com
Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the analyst consensus estimate of $(3.60) by 9.72 percent. This is a 24.52 percent decrease over…
-
6 months ago benzinga.com
Arrowhead Announces Exclusive Worldwide License Agreement With Madrigal For ARO-PNPLA3, Clinical Stage RNAi Therapeutic To Reduce Liver Expression Of PNPLA3 As Potential Treatment For Metabolic Dysfunction-Associated Steatohepatitis
- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH- Phase 1 data published in The New England Journal of…
-
6 months ago benzinga.com
Madrigal Pharmaceuticals Announces Exclusive Global License Agreement With Arrowhead Pharmaceuticals For ARO-PNPLA3
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene,…
8 months ago benzinga.com
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
-
8 months ago benzinga.com
Earnings Scheduled For February 19, 2026
Earnings Scheduled For February 19, 2026
8 months ago benzinga.com
Earnings Preview For Madrigal Pharmaceuticals
Earnings Preview For Madrigal Pharmaceuticals
8 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session
10 Health Care Stocks With Whale Alerts In Today's Session
-
8 months ago benzinga.com
Madrigal Pharmaceuticals inks an exclusive global license agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals for six preclinical MASH programs For An Upfront $60M And Milestone Payment Of $4.4B
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an…
-
9 months ago benzinga.com
Barclays Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $964
Barclays analyst Eliana Merle initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $964.
9 months ago benzinga.com
10 Analysts Have This To Say About Madrigal Pharmaceuticals
10 Analysts Have This To Say About Madrigal Pharmaceuticals